

Report in Brief

Date: August 2017

Report No. A-09-16-02022

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
OFFICE OF INSPECTOR GENERAL



Why OIG Did This Review

For calendar years 2014 and 2015 (audit period), Medicare paid approximately \$1.3 billion for inhalation drugs provided to Medicare beneficiaries nationwide. For the audit period, the Centers for Medicare & Medicaid Services' Comprehensive Error Rate Testing program, which measures improper Medicare fee-for-service payments, found that nebulizers and related drugs (i.e., inhalation drugs) were among the top 20 durable medical equipment, prosthetics, orthotics, and supplies with the highest improper payment rates. After analyzing Medicare claim data for our audit period, we selected three suppliers for review. This report covers one of those suppliers, Accredo Health Group, Inc. (Accredo), which received 26 percent of the total Medicare payments for inhalation drugs.

Our objective was to determine whether Accredo complied with Medicare requirements when billing for inhalation drugs.

How OIG Did This Review

Our review covered 28,718 claim lines for inhalation drugs, for which Accredo received Medicare payments of \$306.7 million. We reviewed a random sample of 100 of these claim lines. For each sampled item, we provided copies of the supporting documentation to a medical review contractor to determine whether inhalation drugs were properly billed.

Accredo Health Group, Inc., Properly Billed Medicare for Inhalation Drugs

What OIG Found

Accredo complied with Medicare requirements when billing for inhalation drugs. Specifically, all 100 sampled claim lines complied with the requirements.

What OIG Recommends

This report has no recommendations.